5 meo dmt mexico

Silo Wellness Partners with Kaivalya Kollectiv to Include 5-MeO-DMT In Psychedelic Portfolio Offering

Silo Wellness Inc. ("Silo Wellness" or "the Company") (CSE: SILO) (FRA: 3K70), a leading global psychedelics company has today announced it will expand its portfolio of psilocybin and ketamine product and retreat offerings to also include 5-MeO-DMT through a partnership with Kaivalya Kollectiv, an L.A.-based wellness company that conducts psychedelic-integrated spiritual coaching as well as facilitated retreats in Mexico, Jamaica and Costa Rica. Through the partnership, Silo Wellness will operate two 5-MeO-DMT retreats in Jamaica, where the Company already conducts psilocybin-assisted retreats as well as mushroom and truffle cultivation workshops. The Company also continues to test its proof-of-concept patent pending nasal spray in Jamaica.

More commonly known by names like the "God molecule" or "The Toad," 5-MeO-DMT is a research chemical psychedelic of the tryptamine class, four to six times more powerful than its better-known cousin, DMT (N,N-dimethyltryptamine). 5-MeO-DMT shows promise in the treatment of certain medical conditions, potentially improving general well-being and mindfulness as well as reducing the symptoms of psychological disorders with a single inhalation.

"Psychedelic experiences can be profoundly transformative and deeply healing. We are pleased to expand our portfolio to include 5-MeO-DMT retreats, especially at a time when so many people are struggling with mental health issues and looking for plant-based alternatives to help guide them on their paths to greater self-actualization," said Douglas K. Gordon, Chief Executive Officer of Silo Wellness.

Silo Wellness and Kaivalya Kollectiv will integrate the 5-MeO-DMT experience into two new Jamaican retreats featuring yoga, meditation, breath work and spiritual coaching as well as unique culinary and cultural experiences. The partnership marks the first by a publicly traded company to offer a 5-MeO-DMT wellness retreat as well as the first-of-its-kind to be held in Jamaica.

"We've always believed that everyone on the planet should have access to the life-changing properties of psychedelics. When used properly, 5-MeO-DMT can be one of the most powerful tools known to man, allowing participants a brief yet intense mystical experience," said Joël Brierre, founder and CEO of Kaivalya Kollectiv. "We are excited to partner with fellow pioneers of the psychedelic industry like Silo Wellness in expanding the resources and tools available to assist people on their journeys towards greater enlightenment and enhanced self-actualization."

5-MeO-DMT is found in a wide variety of plants, at least one toad species and can also be produced synthetically. The compound produces hallucinogenic experiences between 7 and 90 minutes long and has long been used by indigenous communities as a healing modality. Today, 5-MeO-DMT, along with other psychedelic compounds like psilocybin and ketamine, is gaining mainstream popularity as clinical trials and formal research continue to prove its efficacy as an alternative mental health tool and as advocacy initiatives work to decriminalize the compound in certain jurisdictions and adapt the regulations governing its use and applications.

For more information about Silo Wellness psychedelic retreats or to register for one of its psychedelic retreats, visit https://www.silowellness.com/retreats . Each registration is subject to screening and approval by facilitators, and no medical treatment or psychotherapy is offered or available at any retreat. These retreats do not cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

ABOUT SILO WELLNESS
The mission of Silo Wellness is to improve health and wellness by developing and introducing psychedelic medicine to reduce trauma and increase performance by destigmatizing the active compounds in psychedelics and innovating ease of administration and ingestion.   Silo Wellness intends to introduce new, safe, and affordable alternatives to current medicines by facilitating entry into new and emerging markets where psychedelics are legal by conducting ketamine and psilocybin wellness retreats and elsewhere by manufacturing and distributing functional mushrooms.

Since its inception, Silo Wellness' activities have focused on: (1) development of psilocybin-free functional mushroom tinctures; (2) the development of the formulation of a psilocybin nasal spray in Jamaica; and (3) offering of Jamaican and Oregon psychedelic wellness retreats as well as the cultivation of psychedelic mushrooms in Jamaica. None of Silo Wellness's products claim to cure or mitigate any physical or mental disease, symptoms, disorders or abnormalities.

ABOUT KAIVALYA KOLLECTIV

Kaivalya Kollectiv is a multifaceted retreat company focusing on psychedelic wellness and specifically 5-MeO-DMT. Combining ancient eastern and indigenous practices with modern science and western therapies, Kaivalya draws on ‘ancient roots for modern growth.' Kaivalya's main areas of focus are psychedelics / plant medicine, Western and Eastern therapy, biotech and research, yoga/meditation and breathwork.

For further information, please contact:

Media Relations:
Stuart Kirby, VP of Marketing & Communications
press@silowellness.com

Silo Wellness Investor Relations:
(604) 343-2724
IR@empiregroupir.com

Kaivalya Kollective:
joel@kaivalyakollectiv.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION:
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the operations and efficacy of the Company's Oregon and Jamaican retreats, the offering of 5-MeO-DMT retreats and the partnership with Kaivalya Kollectiv, research and decriminalization of psychedelic compounds and the business plans of Silo Wellness. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties and the potential impact of COVID-19. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)

Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis Study with SLS-005

Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today provided an update on top-line data of the Phase 23 HEALEY ALS Platform trial. This study was performed in collaboration with The Sean M. Healey and AMG Center, which is viewed as an influential force in ALS research and in caring for the ALS community. Their unique and innovative approach continues to be a benefit to the ALS community and its contributions have helped bring the last two FDA approved therapies for ALS to market.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health Limited

Appendix 4E Preliminary Final Report Year Ended 31 December 2023

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to present its Preliminary Final Year Report.

Keep reading...Show less

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights 

-

Highlights:
  • COMP360 phase 3 pivotal program ongoing; COMP005 trial top-line data now expected in fourth quarter 2024, COMP006 remains on track for top-line data in mid-2025
  • Teri Loxam to assume Chief Financial Officer role on March 1, 2024
  • Cash position of $220.2 million at December 31, 2023, additional $31.4 million net cash raised to date in first quarter 2024
  • Conference call February 29 at 8:00 am ET (1:00 pm UK)


Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways to participate in upcoming TD Cowen investor conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference at 12:50 pm ET on March 4, 2024.

A live audio webcast of the panel discussion will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following such event. For more information, please visit investor section of compasspathways.com.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2023 ending December 31, 2023, and provide an update on recent business developments, on February 29, 2024.

The management team will host a conference call at 8:00 am ET (1:00 pm UK) on February 29, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Melodiol Global Health Limited

Capital Raising & Corporate Update

Melodiol Global Health Limited (ASX:ME1) (‘Melodiol’ or ‘the Company’) is pleased to advise it has received firm commitments to raise ~$1.08m (before costs) through the issue of approximately 106,415,113 new fully paid ordinary shares (‘Shares’) at an issue price of $0.01019 per Share (the ‘Placement’).

Keep reading...Show less

Latest Press Releases

Related News

×